EA201000612A1 - Антагонисты cgrp-пептиды - Google Patents

Антагонисты cgrp-пептиды

Info

Publication number
EA201000612A1
EA201000612A1 EA201000612A EA201000612A EA201000612A1 EA 201000612 A1 EA201000612 A1 EA 201000612A1 EA 201000612 A EA201000612 A EA 201000612A EA 201000612 A EA201000612 A EA 201000612A EA 201000612 A1 EA201000612 A1 EA 201000612A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
peptides
hydrates
antagonists
cgrp
Prior art date
Application number
EA201000612A
Other languages
English (en)
Inventor
Дирк Готтшлинг
Георг Даманн
Хенри Додс
Аннекатрин Хайманн
Штефан Георг Мюллер
Клаус Рудольф
Герхард Шэнцле
Дирк Штенкамп
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201000612A1 publication Critical patent/EA201000612A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описаны новые антагонисты CGRP-пептида общей формулы (I)в которой U, V, X, Y, R, Rи Rимеют указанные в описании и в формуле изобретения значения, их таутомеры, их изомеры, их диастереомеры, их энантиомеры, их гидраты, их смеси и их соли, а также гидраты солей, прежде всего их физиологически совместимые соли с неорганическими или органическими кислотами, содержащие эти соединения лекарственные средства, их применение и способ их приготовления.
EA201000612A 2007-10-18 2008-10-16 Антагонисты cgrp-пептиды EA201000612A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18
PCT/EP2008/063967 WO2009050234A1 (de) 2007-10-18 2008-10-16 Cgrp-antagonisten

Publications (1)

Publication Number Publication Date
EA201000612A1 true EA201000612A1 (ru) 2010-10-29

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000612A EA201000612A1 (ru) 2007-10-18 2008-10-16 Антагонисты cgrp-пептиды

Country Status (17)

Country Link
US (1) US8450327B2 (ru)
EP (2) EP2386558B1 (ru)
JP (1) JP5366960B2 (ru)
KR (1) KR20100091972A (ru)
CN (1) CN101827845A (ru)
AU (1) AU2008313733A1 (ru)
BR (1) BRPI0817835A2 (ru)
CA (1) CA2702503A1 (ru)
CO (1) CO6270226A2 (ru)
EA (1) EA201000612A1 (ru)
EC (1) ECSP10010105A (ru)
IL (1) IL204928A0 (ru)
MA (1) MA31782B1 (ru)
MX (1) MX2010003849A (ru)
NZ (1) NZ585347A (ru)
TN (1) TN2010000173A1 (ru)
WO (1) WO2009050234A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2251338A3 (de) * 2007-11-22 2011-06-08 Boehringer Ingelheim International GmbH Organische Verbindungen
US8653269B2 (en) 2010-03-12 2014-02-18 Nippon Soda Co., Ltd. Process for preparation of t-butoxycarbonylamine compounds
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
JP6878615B2 (ja) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR015759A1 (es) 1998-04-10 2001-05-16 Searle & Co Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1322628A2 (en) 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
MXPA04011960A (es) 2002-06-05 2005-03-31 Squibb Bristol Myers Co Antagonistas de receptores de peptidos relacionados con el gen de calcitonina.
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006029153A2 (en) 2004-09-08 2006-03-16 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
CA2580020A1 (en) * 2004-09-09 2006-03-23 Ian M. Bell Aryl spirolactam cgrp receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006127588A2 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2006263962A1 (en) 2005-06-29 2007-01-04 Palau Pharma, S.A. Bicyclic derivatives as p38 kinase inhibitors
DE102005050892A1 (de) 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
WO2008070014A2 (en) 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2009034029A2 (de) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
JP2011504481A (ja) 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物
EP2251338A3 (de) 2007-11-22 2011-06-08 Boehringer Ingelheim International GmbH Organische Verbindungen
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen

Also Published As

Publication number Publication date
TN2010000173A1 (fr) 2011-11-11
ECSP10010105A (es) 2010-06-29
NZ585347A (en) 2011-09-30
US20110172218A1 (en) 2011-07-14
CO6270226A2 (es) 2011-04-20
JP2011500637A (ja) 2011-01-06
WO2009050234A1 (de) 2009-04-23
EP2205599A1 (de) 2010-07-14
EP2386558B1 (de) 2014-10-01
EP2386558A1 (de) 2011-11-16
AU2008313733A1 (en) 2009-04-23
IL204928A0 (en) 2010-11-30
JP5366960B2 (ja) 2013-12-11
MA31782B1 (fr) 2010-10-01
US8450327B2 (en) 2013-05-28
CN101827845A (zh) 2010-09-08
KR20100091972A (ko) 2010-08-19
CA2702503A1 (en) 2009-04-23
BRPI0817835A2 (pt) 2015-03-31
MX2010003849A (es) 2010-04-27
EP2205599B1 (de) 2012-06-06

Similar Documents

Publication Publication Date Title
EA201000612A1 (ru) Антагонисты cgrp-пептиды
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
EA200601621A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
WO2009065919A3 (de) Organische verbindungen
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2009065920A3 (de) Verbindungen
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
EA201100037A1 (ru) Органические соединения
EA201170772A1 (ru) Органические соединения
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA200500601A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
EA201201167A1 (ru) Соединения в качестве антагонистов брадикинина b1
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200500600A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
EA200970156A1 (ru) Пиридизиноновые производные
ECSP109953A (es) Derivados de piridazinona
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
EA200702620A1 (ru) ЗАМЕЩЕННЫЕ ГЛИЦИНАМИДЫ С АНТИТРОМБОТИЧЕСКИМ И ИНГИБИРУЮЩИМ ФАКТОР Xa ДЕЙСТВИЕМ
WO2009065922A3 (de) Organische verbindungen
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions